StockVS

NASDAQ · USD

NewAmsterdam Pharma Company N.V. (NAMSW) Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMSW) is a stock listed on NASDAQ and quoted in US Dollar.

NAMSW

$13.88

−$0.56 (−3.88%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on NewAmsterdam Pharma Company N.V. (NAMS) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View NAMS →

Price History

Hover for the daily close. The dotted line marks the period open.

NAMSW Key Statistics

As of Sep 4, 2026
Trading
Open
$13.88
Previous Close
$14.44
52-Week Range
12.69–30.45
Volume
100
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.09

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NAMSW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.65%
2025+61.40%
2024+355.27%
2023+260.60%
2022+47.37%
2021 (partial year)−76.90%

As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Visit website →